Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, Paul J, Gramme P, Ost P.

World J Urol. 2018 Dec 21. doi: 10.1007/s00345-018-2609-8. [Epub ahead of print]

PMID:
30578441
2.

The biology of prostate cancer metastases: does oligo differ from polymetastatic?

Sonpavde G.

Curr Opin Urol. 2017 Nov;27(6):542-546. doi: 10.1097/MOU.0000000000000434. Review.

PMID:
28786848
3.

Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.

Sun Z, Zhou S, Tang J, Ye T, Li J, Liu D, Zhou J, Wang J, Rosie Xing H.

EBioMedicine. 2018 Nov;37:47-55. doi: 10.1016/j.ebiom.2018.10.002. Epub 2018 Oct 6.

4.

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.

Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, Delrue L, Billiet I, Duthoy W, Junius S, Huysse W, Lumen N, Ost P.

BMC Cancer. 2014 Sep 15;14:671. doi: 10.1186/1471-2407-14-671.

5.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
6.

Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.

Barzilai O, Versteeg AL, Sahgal A, Rhines LD, Bilsky MH, Sciubba DM, Schuster JM, Weber MH, Pal Varga P, Boriani S, Bettegowda C, Fehlings MG, Yamada Y, Clarke MJ, Arnold PM, Gokaslan ZL, Fisher CG, Laufer I, The Ao Spine Knowledge Forum Tumor.

Cancer. 2019 Mar 1;125(5):770-778. doi: 10.1002/cncr.31870. Epub 2018 Nov 29.

PMID:
30489634
7.

Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.

Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, Wang J, Yuan ZY, Zhao LJ, Wang P.

Sci Rep. 2017 Aug 23;7(1):9255. doi: 10.1038/s41598-017-09775-0.

8.

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot JN, Zacho H, Tombal B, deSouza NM.

Lancet Oncol. 2018 Oct;19(10):e534-e545. doi: 10.1016/S1470-2045(18)30571-0. Epub 2018 Oct 1. Review.

PMID:
30303127
9.

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G.

J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14.

PMID:
29240541
10.

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.

Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2017 Oct;15(5):e773-e782. doi: 10.1016/j.clgc.2017.03.009. Epub 2017 Mar 29.

PMID:
28462855
11.

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.

Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D'Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM.

Br J Cancer. 2017 Jun 6;116(12):1520-1525. doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27.

12.

MicroRNA expression characterizes oligometastasis(es).

Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR.

PLoS One. 2011;6(12):e28650. doi: 10.1371/journal.pone.0028650. Epub 2011 Dec 13.

13.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.

Joice GA, Rowe SP, Pienta KJ, Gorin MA.

Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449. Review.

PMID:
28863016
14.

[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.

Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, Ferrazza P, Coraggio G, Pasqualetti G, Derosa L, Sollini M, Mannelli L, Ortori S, Monzani F, Ricci S, Greco C, Fabrini MG, Erba PA.

Radiat Oncol. 2016 Jan 22;11:9. doi: 10.1186/s13014-016-0586-x.

15.

Oligometastasis and oligo-recurrence: more than a mirage.

Huang F, Wu G, Yang K.

Radiat Oncol. 2014 Oct 31;9:230. doi: 10.1186/s13014-014-0230-6. Review.

16.

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.

Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR.

Clin Exp Metastasis. 2014 Aug;31(6):735-48. doi: 10.1007/s10585-014-9664-3. Epub 2014 Jun 27. Review.

17.

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.

PMID:
20848281
18.

Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.

Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK.

PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149. eCollection 2018.

19.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.

De Bleser E, Tran PT, Ost P.

Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441. Review.

PMID:
28816714
20.

The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.

Kucharczyk MJ, Gravis G, Niazi T.

Eur Urol Focus. 2018 Dec 4. pii: S2405-4569(18)30372-9. doi: 10.1016/j.euf.2018.11.011. [Epub ahead of print]

PMID:
30527643

Supplemental Content

Support Center